13-Mar-2026
PRNewswire (Wed, 11-Mar 9:00 AM ET)
PRNewswire (Tue, 10-Mar 9:01 AM ET)
PRNewswire (Wed, 4-Mar 9:00 AM ET)
PRNewswire (Tue, 3-Mar 9:00 AM ET)
Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
Globe Newswire (Mon, 2-Mar 7:00 AM ET)
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Feb 6:30 AM ET)
Globe Newswire (Mon, 26-Jan 7:00 AM ET)
Globe Newswire (Mon, 12-Jan 7:00 AM ET)
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Globe Newswire (Mon, 5-Jan 7:00 AM ET)
Market Chameleon (Wed, 24-Dec 5:33 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of March 13, 2026, AGIO stock price climbed to $27.85 with 487,513 million shares trading.
AGIO has a beta of 2.07, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.25 to the broad based SPY ETF.
AGIO has a market cap of $1.63 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $20 million in Revenue and -$1.86 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.10.
In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, XBI, IWM, VB, VBK.
AGIO has underperformed the market in the last year with a price return of -12.9% while the SPY ETF gained +19.8%. However, in the short term, AGIO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.1% vs -2.6% return in SPY. But in the last 2 weeks, AGIO shares have been beat by the market, returning -7.1% compared to an SPY return of -3.9%.
AGIO support price is $26.83 and resistance is $28.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.